Saturday 17 October 2026
Export CNSY’s income statement to Excel — free account
Cerenome, Inc.
CNSY Healthcare Biotechnology
Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024. In the quarter to June 2026, revenue fell 70.4%, EPS fell 362.0% and free cash flow fell 31.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.70
0.18
−9.57%
Follow CNSY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| (520.84%) | 204.30% | 903.94% | 40,893.33% | ||
| (181.53%) | (74.63%) | (195.02%) | (191.33%) | ||
ROIC |
(532.77%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(479.69%) | (107.62%) | (719.11%) | (578.27%) | |
Average Days of Receivables |
152.93 | 95.09 | 22.55 | 0.00 | |
Free Cash Flow per Share |
(3.41) | (3.27) | (6.69) | (3.79) | |
Free Cash Flow |
(23.55) | (21.72) | (20.81) | (16.30) | |
Capital Expenditures |
(1.37) | (0.88) | (0.04) | (0.57) | |
| Other line items | |||||
Cash ROIC |
(300.79%) | (78.30%) | (154.12%) | (75.27%) | |
Accounts Receivable Turnover |
3.60 | 7.19 | 10.03 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | 0.00 | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | — | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
297.57% | 183.10% | 160.73% | 145.00% | |
Selling, General and Administrative Expense of Revenue |
430.55% | 281.26% | 232.73% | 210.92% | |
Share Based Compensation of Revenue |
73.57% | 46.58% | 29.54% | 18.16% | |
Interest Coverage |
(42.11) | (27.64) | — | — | |
Operating CF/Net income |
1.00 | 1.75 | 0.93 | 0.64 | |
Depreciation/Fixed assets |
0.32 | 0.39 | 1.73 | 2.30 | |
Capex/Depreciation |
(3.02) | (2.23) | (0.08) | (0.91) | |
Revenue per Share |
0.61 | 0.78 | 1.68 | 1.22 | |
Operating CF per Share |
(3.21) | (3.14) | (6.68) | (3.66) | |
Capex per Share |
(0.20) | (0.13) | (0.01) | (0.13) | |
Capex to Sales |
0.33 | 0.17 | 0.01 | 0.11 |
Columns are period end dates